-+ 0.00%
-+ 0.00%
-+ 0.00%

Shanghai Yizhong announced that the company recently received the “Drug Clinical Trial Approval Notice” issued by the State Drug Administration, and the clinical trial application for the self-developed innovative drug YXC-002 for the treatment of non-small cell lung cancer has been officially approved.

Zhitongcaijing·08/18/2026 11:17:02
Listen to the news
Shanghai Yizhong announced that the company recently received the “Drug Clinical Trial Approval Notice” issued by the State Drug Administration, and the clinical trial application for the self-developed innovative drug YXC-002 for the treatment of non-small cell lung cancer has been officially approved.